Lainate – April 21, 2020 – Cassiopea SpA (SIX: SKIN), a clinical stage specialty pharmaceutical company focused on developing innovative and differentiated medical dermatology products, today announced the lists of candidates proposed for the board of directors at the Annual General Meeting of 29 April 2020, in Lainate, Milan (Italy).
The list proposed by Cassiopea’s shareholder Cosmo Pharmaceuticals NV consists of the following candidates: Jan de Vries (incumbent, non-executive, independent), Pierpaolo Guzzo (incumbent, non-executive, independent), Oyvind Bjordal (incumbent, non-executive, independent), and Diana Harbort (incumbent, executive). The proposed list is available here on the Company’s website.
The list proposed by Cassiopea’s shareholder Heinrich Herz AG/Logistable SA Group consists of the following candidate: Maurizio Baldassarini (incumbent, non-executive, independent). The proposed list is available here on the Company’s website.
Owing to the COVID-19 health emergency and in compliance with art. 106 of Law-Decree n. 18 dated March 17, 2020 aimed at minimizing travel and gatherings, attending and voting at the Shareholders’ Meeting can only occur through the granting of a specific proxy to the designated representative (Dario Trevisan, lawyer).
In particular pursuant to art. 106, paragraph 4, of Law-Decree n. 18 dated March 17, 2020, participation in the meeting can occur exclusively through the designated representative (Dario Trevisan, lawyer). Pursuant to article 135-undecies of Legislative Decree No. 58 dated February 24, 1998; the designated representative (Dario Trevisan, lawyer) may also be granted proxies and/or sub-proxies pursuant to article 135-novies of Legislative Decree No. 58 dated February 24, 1998, in deviation from art. 135-undecies, paragraph 4, of the same Decree. All operative details are available at Company’s website www.cassiopea.com in the section “Investor/Corporate Governance”.
Cassiopea is a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia and genital warts. Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. If approved, Cassiopea plans to commercialize the products directly in the USA and partner the products for countries outside of the USA. For further information on Cassiopea, please visit www.cassiopea.com.
|Annual General Shareholders Meeting –||29 April 2020, Lainate|
|Extraordinary Shareholders Meeting –||28 May 2020, Lainate|
|Jefferies Global Health Care Conference –||2-4 June 2020, New York|
|Half Year Report 2020||July 2020|
|Investora –||23-24 September 2020, Zürich|
|Credit Suisse Small & Mid Cap Conference –||18-20 November 2020, Zurich|
Dr. Chris Tanner, CFO and Head of Investor Relations
Tel: +39 02 868 91 124
Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cassiopea has no obligation to publicly update or revise any forward-looking statements.